Clinical relevance of molecular characteristics in Burkitt lymphoma differs according to age.

Autor: Burkhardt B; Pediatric Hematology, Oncology and BMT, University Hospital Münster, Münster, Germany. birgit.burkhardt@ukmuenster.de., Michgehl U; Pediatric Hematology, Oncology and BMT, University Hospital Münster, Münster, Germany., Rohde J; Pediatric Hematology, Oncology and BMT, University Hospital Münster, Münster, Germany., Erdmann T; Department of Medicine A, Hematology, Oncology, and Pneumology, University Hospital Münster, Münster, Germany., Berning P; Department of Medicine A, Hematology, Oncology, and Pneumology, University Hospital Münster, Münster, Germany., Reutter K; Pediatric Hematology, Oncology and BMT, University Hospital Münster, Münster, Germany., Rohde M; Pediatric Hematology and Oncology, University Hospital Giessen, Giessen, Germany., Borkhardt A; Department of Pediatric Oncology, Hematology and Clinical Immunology, University Children's Hospital Medical Faculty, Heinrich-Heine-University, Düsseldorf, Germany., Burmeister T; Department of Hematology, Oncology and Tumor Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany., Dave S; Center for Genomic and Computational Biology and Department of Medicine, Duke University, Durham, NC, USA., Tzankov A; Pathology, Institute of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland., Dugas M; Institute of Medical Informatics, Heidelberg University Hospital, Heidelberg, Germany., Sandmann S; Institute of Medical Informatics, University of Münster, Münster, Germany., Fend F; Institute of Pathology and Neuropathology and Comprehensive Cancer Centre Tübingen, University Hospital Tübingen, Eberhard-Karls-University, Tübingen, Germany., Finger J; Pediatric Hematology, Oncology and BMT, University Hospital Münster, Münster, Germany., Mueller S; Pediatric Hematology, Oncology and BMT, University Hospital Münster, Münster, Germany., Gökbuget N; Department of Medicine II, Goethe University, Frankfurt, Germany., Haferlach T; MLL Munich Leukemia Laboratory, Munich, Germany., Kern W; MLL Munich Leukemia Laboratory, Munich, Germany., Hartmann W; Division of Translational Pathology, Gerhard-Domagk-Institute of Pathology, University Hospital of Münster, Münster, Germany., Klapper W; Department of Pathology, Hematopathology Section, University Hospital Schleswig-Holstein, Kiel, Germany., Oschlies I; Department of Pathology, Hematopathology Section, University Hospital Schleswig-Holstein, Kiel, Germany., Richter J; Department of Pathology, Hematopathology Section, University Hospital Schleswig-Holstein, Kiel, Germany., Kontny U; Section of Pediatric Hematology, Oncology, and Stem Cell Transplantation, Department of Pediatric and Adolescent Medicine, RWTH Aachen University Hospital, Aachen, Germany., Lutz M; Hematology and Oncology, Medical Faculty, University of Augsburg, Augsburg, Germany., Maecker-Kolhoff B; Hannover Medical School, Department of Pediatric Hematology and Oncology, Hannover, Germany., Ott G; Department of Clinical Pathology, Robert-Bosch-Krankenhaus, and Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany., Rosenwald A; Institute of Pathology, Universität Würzburg and Comprehensive Cancer Centre Mainfranken (CCCMF), Würzburg, Germany., Siebert R; Institute of Human Genetics, Ulm University and Ulm University Medical Center, Ulm, Germany., von Stackelberg A; Department of Pediatric Oncology Hematology, Charité - Universitätsmedizin Berlin, Berlin, Germany., Strahm B; Department of Pediatrics and Adolescent Medicine Division of Pediatric Hematology and Oncology, Medical Center Faculty of Medicine, University of Freiburg, Freiburg im Breisgau, Germany., Woessmann W; Pediatric Hematology and Oncology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany., Zimmermann M; Hannover Medical School, Department of Pediatric Hematology and Oncology, Hannover, Germany., Zapukhlyak M; Department of Medicine A, Hematology, Oncology, and Pneumology, University Hospital Münster, Münster, Germany., Grau M; Department of Medicine A, Hematology, Oncology, and Pneumology, University Hospital Münster, Münster, Germany., Lenz G; Department of Medicine A, Hematology, Oncology, and Pneumology, University Hospital Münster, Münster, Germany.
Jazyk: angličtina
Zdroj: Nature communications [Nat Commun] 2022 Jul 06; Vol. 13 (1), pp. 3881. Date of Electronic Publication: 2022 Jul 06.
DOI: 10.1038/s41467-022-31355-8
Abstrakt: While survival has improved for Burkitt lymphoma patients, potential differences in outcome between pediatric and adult patients remain unclear. In both age groups, survival remains poor at relapse. Therefore, we conducted a comparative study in a large pediatric cohort, including 191 cases and 97 samples from adults. While TP53 and CCND3 mutation frequencies are not age related, samples from pediatric patients showed a higher frequency of mutations in ID3, DDX3X, ARID1A and SMARCA4, while several genes such as BCL2 and YY1AP1 are almost exclusively mutated in adult patients. An unbiased analysis reveals a transition of the mutational profile between 25 and 40 years of age. Survival analysis in the pediatric cohort confirms that TP53 mutations are significantly associated with higher incidence of relapse (25 ± 4% versus 6 ± 2%, p-value 0.0002). This identifies a promising molecular marker for relapse incidence in pediatric BL which will be used in future clinical trials.
(© 2022. The Author(s).)
Databáze: MEDLINE
Externí odkaz: